Urokinase is a direct plasminogen activator widely used in thrombotic diseases, especially in the Asian market. Due to the risk of bleeding, strict control of indications and dosages is required. Advances in recombinant technology have made its production safer and more efficient.
*The following content is generated by AI and is for reference only.
Urokinase, also known as urokinase-type plasminogen activator (uPA), is a serine protease enzyme with significant clinical applications in the field of thrombolytic therapy. Its molecular formula is C254H396N68O79S10, and it carries the CAS Registry Number 9002-05-9. Originally isolated from human urine, this biologically active protein plays a crucial role in the fibrinolytic system by converting plasminogen into plasmin, an enzyme responsible for breaking down blood clots.
The primary therapeutic use of Urokinase is in the management of acute myocardial infarction, pulmonary embolism, and deep vein thrombosis. By dissolving existing clots, it helps restore blood flow to ischemic tissues, thereby reducing the risk of permanent organ damage or death. Unlike some other thrombolytics, Urokinase exhibits high specificity for plasminogen activation without directly degrading fibrinogen, although systemic bleeding remains a potential side effect that requires careful monitoring during administration.
Beyond its established medical uses, Urokinase has attracted attention in research regarding cancer metastasis. The uPA system is often overexpressed in various tumor types, facilitating tissue invasion and angiogenesis. Consequently, inhibitors targeting uPA are being investigated as potential anti-cancer agents. In industrial and laboratory settings, recombinant forms of Urokinase are produced using genetic engineering techniques to ensure purity and consistency for pharmaceutical manufacturing. These recombinant versions offer advantages over plasma-derived preparations, including reduced immunogenicity and higher yield.
Despite the emergence of newer thrombolytic agents like tPA, Urokinase remains a vital tool in specific clinical scenarios where cost-effectiveness or particular pharmacokinetic profiles are required. Its mechanism of action underscores the delicate balance between clot dissolution and hemostasis maintenance. Ongoing studies continue to explore novel delivery methods and combination therapies to enhance efficacy while minimizing hemorrhagic complications. As a cornerstone of modern thrombolytic treatment, Urokinase exemplifies the intersection of biochemistry and clinical medicine, saving countless lives through targeted enzymatic intervention in vascular occlusion events worldwide.